Oxford Biotrans, based at Milton Park, has closed £2.1 million in new funding. The investment was led by Touchstone Innovations (formerly Imperial Innovations) with participation from existing shareholders including the University of Oxford and Oxford Investment Consultants/Oxford Technology and Innovations EIS Fund, alongside new investment from Perivoli Innovations.
The company commercialises new natural routes to high value chemicals, based on its patented enzyme technology. The first product is natural grade nootkatone, the flavour and scent of grapefruit, which the company began to manufacture in commercial quantities earlier this year.
Will Barton, Chairman of Oxford Biotrans said: “We are delighted that our major investors have continued to support us through this new funding round and that we have also been able to attract a new investor to the fold. The business has built a solid foundation that now supports a step up in headcount and work space which will be exploited to take our exciting pipeline of development products to market.”